Literature DB >> 3234483

Serotonergic regulation of noradrenergic coerulean neurons: electrophysiological evidence for the involvement of 5-HT2 receptors.

E Gorea1, J Adrien.   

Abstract

To determine the type of serotonergic receptor involved in the modulation of noradrenergic neuronal activity in the locus coeruleus, the effects of 4 systemically administered serotonergic drugs were tested on the firing rate of noradrenergic neurons in the locus coeruleus of rats under chloral hydrate anaesthesia. The serotonergic agonist, quipazine (1 mg/kg), and the selective 5-HT2 agonist, DOB (50-100 micrograms/kg), induced a pronounced decrease of the discharge frequency. This effect could be prevented or reversed by the selective 5-HT2 antagonist, ketanserin (4-8 mg/kg). Ketanserin alone and the 5-HT1 agonist, RU 24969, had no or a weak excitatory action on the neuronal activity of the locus coeruleus. We conclude that the serotonergic control of noradrenergic neurons in the locus coeruleus is mediated by post-synaptic 5-HT2 receptors because the quipazine-ketanserin effects on this unit activity persisted after depletion of serotonergic presynaptic stores.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3234483     DOI: 10.1016/0014-2999(88)90203-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  The sleep-wake cycle and motor activity, but not temperature, are disrupted over the light-dark cycle in mice genetically depleted of serotonin.

Authors:  Julia Z Solarewicz; Mariana Angoa-Perez; Donald M Kuhn; Jason H Mateika
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-11-12       Impact factor: 3.619

2.  Acute and chronic effects of the atypical antidepressant, mianserin on brain noradrenergic neurons.

Authors:  A L Curtis; R J Valentino
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Effects of lesioning of the medial cervical nucleus on the baseline spike activity of neurons in the central and basolateral nuclei of the amygdala.

Authors:  M V Khanbabyan; M P Kirakosyan; R Sh Sarkisyan; A P Gevorkyan
Journal:  Neurosci Behav Physiol       Date:  2006-01

4.  Effect of noradrenergic system on the anxiolytic-like effect of DOI (5-HT2A/2C agonists) in the four-plate test.

Authors:  Fabienne Massé; Martine Hascoët; Eric Dailly; Michel Bourin
Journal:  Psychopharmacology (Berl)       Date:  2005-11-24       Impact factor: 4.530

5.  Repeated exposure to MDMA triggers long-term plasticity of noradrenergic and serotonergic neurons.

Authors:  C Lanteri; E L Doucet; S J Hernández Vallejo; G Godeheu; A-C Bobadilla; L Salomon; L Lanfumey; J-P Tassin
Journal:  Mol Psychiatry       Date:  2013-08-20       Impact factor: 15.992

6.  Retarded acquisition of a temporal discrimination following destruction of noradrenergic neurones by systemic treatment with DSP4.

Authors:  M Y Ho; D N Velazquez Martinez; M Lopez Cabrera; S S al-Zahrani; C M Bradshaw; E Szabadi
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

Review 7.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

8.  Evidence that 5-HT2 receptor activation decreases noradrenaline release in rat hippocampus in vivo.

Authors:  C J Done; T Sharp
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

9.  Increase of noradrenaline release in the hypothalamus of freely moving rat by postsynaptic 5-hydroxytryptamine1A receptor activation.

Authors:  M Suzuki; T Matsuda; S Asano; P Somboonthum; K Takuma; A Baba
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

10.  Involvement of serotonin 5-HT3 receptors in the modulation of noradrenergic transmission by serotonin reuptake inhibitors: a microdialysis study in rat brain.

Authors:  Begoña Fernández-Pastor; Jorge E Ortega; J Javier Meana
Journal:  Psychopharmacology (Berl)       Date:  2013-05-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.